MOHAMED HEGAZI MD
Prescription History 1003206392
Internal Medicine - Hematology & Oncology in Louisville, KY


Quality Rating: 73.19 out of 100 score

NPI Status: Active since January 26, 2015

Contact Information

529 S JACKSON ST
LOUISVILLE, KY
ZIP 40202
Phone: (502) 562-4270

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MOHAMED HEGAZI MD, an active Hematology & Oncology specialist practicing in Louisville, KY. Our medical registry currently tracks 20 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 527 documented patient claims. Among these therapy options, the most frequently utilized medication is Acyclovir, which accounts for 71 claims alone.


Acyclovir

Generic Formulation: AcyclovirSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 71
30-Day Fills 93.0
Days Supply 2,790
KY State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills31.0
Peer Average Days Supply776
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 238.1% higher than the standard regional baseline profile for KY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,008.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.21

State Avg Cost Per Claim

$21.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.

Therapeutic Applications

Acyclovir is used to treat infections caused by certain types of viruses. It treats cold sores around the mouth (caused by herpes simplex), shingles (caused by herpes zoster), and chickenpox. This medication is also used to treat outbreaks of genital herpes. In people with frequent outbreaks, acyclovir is used to help reduce the number of future episodes. Acyclovir is an antiviral drug. However, it is not a cure for these infections. The viruses that cause these infections continue to live in the body even between outbreaks. Acyclovir decreases the severity and length of these outbreaks. It helps the sores heal faster, keeps new sores from forming, and decreases pain/itching. This medication may also help reduce how long pain remains after the sores heal. In addition, in people with a weakened immune system, acyclovir can decrease the risk of the virus spreading to other parts of the body and causing serious infections.

Brukinsa

Generic Formulation: ZanubrutinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 34
30-Day Fills 34.0
Days Supply 1,020
KY State Average Benchmarks
Peer Average Claims16.0
Peer Average 30-Day Fills16.1
Peer Average Days Supply480
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 112.5% higher than the standard regional baseline profile for KY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $529,949.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,586.74

State Avg Cost Per Claim

$13,338.18

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (mantle cell lymphoma, marginal zone lymphoma, Waldenstrom's macroglobulinemia). Zanubrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells.

Calquence

Generic Formulation: Acalabrutinib MaleateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
KY State Average Benchmarks
Peer Average Claims11.0
Peer Average 30-Day Fills12.0
Peer Average Days Supply360
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across KY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $188,281.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,690.14

State Avg Cost Per Claim

$13,640.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as mantle cell lymphoma, small lymphocytic lymphoma - SLL, chronic lymphocytic leukemia - CLL). Acalabrutinib works by slowing or stopping the growth of cancer cells. It belongs to a class of drugs known as kinase inhibitors.

Dexamethasone

Generic Formulation: DexamethasoneSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.2
Days Supply 354
KY State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills30.7
Peer Average Days Supply369
Conservative Utilization

This provider writes prescriptions for this formulation 44.8% less frequently than the standard regional baseline metric for practitioners inside KY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $255.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.95

State Avg Cost Per Claim

$13.55

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anti-inflammatory 9-fluoro-glucocorticoid.

Therapeutic Applications

Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions, skin diseases, eye problems, breathing problems, bowel disorders, cancer, and immune system disorders. It is also used as a test for an adrenal gland disorder (Cushing's syndrome). Dexamethasone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Gabapentin

Generic Formulation: GabapentinSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 60
30-Day Fills 64.0
Days Supply 1,920
KY State Average Benchmarks
Peer Average Claims162.0
Peer Average 30-Day Fills192.6
Peer Average Days Supply5,572
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.0% less volume than the regional standard for practitioners inside KY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $723.02 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.05

State Avg Cost Per Claim

$15.61

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.

Therapeutic Applications

Gabapentin is used with other medications to prevent and control seizures. It is also used to relieve nerve pain following shingles (a painful rash due to herpes zoster infection) in adults. Gabapentin is known as an anticonvulsant or antiepileptic drug.

Imatinib Mesylate

Generic Formulation: Imatinib MesylateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 33
30-Day Fills 33.0
Days Supply 990
KY State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills22.9
Peer Average Days Supply681
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 50.0% more claims than the standard regional baseline profile for KY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $85,832.56 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,600.99

State Avg Cost Per Claim

$2,740.92

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A tyrosine kinase inhibitor and ANTINEOPLASTIC AGENT that inhibits the BCR-ABL kinase created by chromosome rearrangements in CHRONIC MYELOID LEUKEMIA and ACUTE LYMPHOBLASTIC LEUKEMIA, as well as PDG-derived tyrosine kinases that are overexpressed in gastrointestinal stromal tumors.

Therapeutic Applications

This medication is used to treat certain types of cancer (such as acute lymphoblastic leukemia, chronic myeloid leukemia, gastrointestinal stromal tumors, and myelodysplastic/myeloproliferative diseases). It works by slowing or stopping the growth of cancer cells. Imatinib may also be used to treat certain immune system disorders (such as aggressive systemic mastocytosis, hypereosinophilic syndrome).

Imbruvica

Generic Formulation: IbrutinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 24
30-Day Fills 24.0
Days Supply 672
KY State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills35.6
Peer Average Days Supply1,004
Conservative Utilization

This provider writes prescriptions for this formulation 31.4% less frequently than the standard regional baseline metric for practitioners inside KY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $402,782.09 across this reporting matrix range.

Provider Avg Cost Per Claim

$16,782.59

State Avg Cost Per Claim

$14,706.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia). Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Ibrutinib is also used to treat a certain problem that may occur after a stem cell transplant (chronic graft versus host disease). It works by weakening your body's defense system (immune system).

Jakafi

Generic Formulation: Ruxolitinib PhosphateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 420
KY State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills23.8
Peer Average Days Supply713
Conservative Utilization

This provider writes prescriptions for this formulation 39.1% less frequently than the standard regional baseline metric for practitioners inside KY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $266,081.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$19,005.82

State Avg Cost Per Claim

$16,389.24

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bone marrow disorders (myelofibrosis, polycythemia vera). It works by blocking your body from producing substances called growth factors. Growth factors cause cells to grow and divide, and cause the blood cell and spleen problems found in these disorders. Ruxolitinib belongs to a class of drugs known as kinase inhibitors. Though not a cure for these disorders, ruxolitinib may help with some of the symptoms, including abdominal discomfort, pain under left ribs, early feelings of fullness from meals, night sweats, itching, and bone/muscle pain. Ruxolitinib is also used to treat a certain problem that may occur after certain stem cell or bone marrow transplants (graft versus host disease). It works by weakening your body's defense system (immune system).

Lenalidomide

Generic Formulation: LenalidomideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 62
30-Day Fills 62.0
Days Supply 1,722
KY State Average Benchmarks
Peer Average Claims13.0
Peer Average 30-Day Fills13.1
Peer Average Days Supply339
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 376.9% higher than the standard regional baseline profile for KY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $792,659.69 across this reporting matrix range.

Provider Avg Cost Per Claim

$12,784.83

State Avg Cost Per Claim

$13,190.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Ninlaro

Generic Formulation: Ixazomib CitrateSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 532
KY State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills17.8
Peer Average Days Supply491
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across KY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $249,101.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$13,110.60

State Avg Cost Per Claim

$12,428.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat a certain type of cancer (multiple myeloma). It works by slowing or stopping the growth of cancer cells.

Ondansetron Odt

Generic Formulation: OndansetronSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 185
KY State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills28.8
Peer Average Days Supply310
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.7% less volume than the regional standard for practitioners inside KY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $174.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$15.89

State Avg Cost Per Claim

$22.84

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.

Therapeutic Applications

This medication is used alone or with other medications to prevent nausea and vomiting caused by cancer drug treatment (chemotherapy) and radiation therapy. It is also used to prevent and treat nausea and vomiting after surgery. Ondansetron works by blocking one of the body's natural substances (serotonin) that causes vomiting.

Oxycodone Hcl

Generic Formulation: Oxycodone HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 279
KY State Average Benchmarks
Peer Average Claims71.0
Peer Average 30-Day Fills71.8
Peer Average Days Supply1,527
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 71.8% less volume than the regional standard for practitioners inside KY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $472.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.61

State Avg Cost Per Claim

$22.90

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic derivative of CODEINE.

Therapeutic Applications

This medication is used to help relieve moderate to severe pain. Oxycodone belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Pegasys

Generic Formulation: Peginterferon Alfa-2aSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 364
KY State Average Benchmarks
Peer Average Claims12.0
Peer Average 30-Day Fills12.5
Peer Average Days Supply356
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across KY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $53,678.48 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,129.11

State Avg Cost Per Claim

$4,410.03

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Peginterferon alfa-2a is used alone or in combination with other medications to treat chronic hepatitis B and chronic hepatitis C, viral infections of the liver. It works by decreasing the amount of hepatitis virus in the body and helps your body's natural defense (immune system) fight the infection. Chronic hepatitis infection can lead to serious liver damage (cirrhosis) and liver cancer. It is not known if peginterferon can cure hepatitis B or hepatitis C infections or can prevent you from passing the virus to others. Practice safer sex (such as the use of latex condoms) to lower the risk of passing the virus to others.

Pomalyst

Generic Formulation: PomalidomideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 392
KY State Average Benchmarks
Peer Average Claims19.0
Peer Average 30-Day Fills19.5
Peer Average Days Supply539
Conservative Utilization

This provider writes prescriptions for this formulation 26.3% less frequently than the standard regional baseline metric for practitioners inside KY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $418,110.37 across this reporting matrix range.

Provider Avg Cost Per Claim

$29,865.03

State Avg Cost Per Claim

$20,163.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Pomalidomide is used to treat certain types of cancers (such as multiple myeloma, Kaposi sarcoma). It works by slowing or stopping the growth of cancer cells.

Pregabalin

Generic Formulation: PregabalinSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 18
30-Day Fills 18.0
Days Supply 540
KY State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills58.7
Peer Average Days Supply1,713
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 64.7% less volume than the regional standard for practitioners inside KY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,437.78 across this reporting matrix range.

Provider Avg Cost Per Claim

$135.43

State Avg Cost Per Claim

$40.07

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA.

Therapeutic Applications

This medication is used to treat pain caused by nerve damage due to diabetes, shingles (herpes zoster) infection, or spinal cord injury. This medication is also used to treat pain in people with fibromyalgia. It is also used with other medications to treat certain types of seizures (focal seizures).

Revlimid

Generic Formulation: LenalidomideSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 16
30-Day Fills 16.0
Days Supply 448
KY State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills38.6
Peer Average Days Supply1,027
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 57.9% less volume than the regional standard for practitioners inside KY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $336,301.16 across this reporting matrix range.

Provider Avg Cost Per Claim

$21,018.82

State Avg Cost Per Claim

$18,272.65

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Rydapt

Generic Formulation: MidostaurinSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 301
KY State Average Benchmarks
Peer Average Claims11.0
Peer Average 30-Day Fills11.0
Peer Average Days Supply308
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across KY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $129,725.33 across this reporting matrix range.

Provider Avg Cost Per Claim

$11,793.21

State Avg Cost Per Claim

$14,564.68

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Midostaurin is used to treat certain types of blood cell cancer (acute myeloid leukemia-AML, mast cell leukemia-MCL) or an immune system disorder (mastocytosis). It works by slowing or stopping the growth of cancer cells and certain immune system cells (mast cells).

Sprycel

Generic Formulation: DasatinibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 690
KY State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills18.5
Peer Average Days Supply552
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 27.8% more claims than the standard regional baseline profile for KY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $422,148.51 across this reporting matrix range.

Provider Avg Cost Per Claim

$18,354.28

State Avg Cost Per Claim

$13,064.31

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrimidine and thiazole derived ANTINEOPLASTIC AGENT and PROTEIN KINASE INHIBITOR of BCR-ABL KINASE. It is used in the treatment of patients with CHRONIC MYELOID LEUKEMIA who are resistant or intolerant to IMATINIB.

Therapeutic Applications

This medication is used to treat certain types of cancer (chronic myeloid leukemia-CML, acute lymphoblastic leukemia-ALL). It works by slowing or stopping the growth of cancer cells.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 34
30-Day Fills 39.5
Days Supply 822
KY State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills26.9
Peer Average Days Supply321
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 36.0% more claims than the standard regional baseline profile for KY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $106.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$3.14

State Avg Cost Per Claim

$5.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Venclexta

Generic Formulation: VenetoclaxSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 22
30-Day Fills 22.0
Days Supply 642
KY State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.2
Peer Average Days Supply580
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across KY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $344,151.57 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,643.25

State Avg Cost Per Claim

$8,854.51

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of cancer (chronic lymphocytic leukemia-CLL, small lymphocytic lymphoma-SLL, acute myeloid leukemia-AML). Venetoclax is a drug that works by helping to slow or stop the growth of cancer cells.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MOHAMED HEGAZI MD provides transparency into local medical care patterns within Louisville, KY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.